Fatty Acid

Propionate

Propionic acid colonic-delivery intervention (commonly inulin-propionate ester)

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

10-20 g/day

watchEffect Window

Acute to short-term for appetite. Mixed over longer-term body-weight endpoints.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Propionate has a credible short-term appetite signal, but the best long-term trial did not show clear superiority over inulin for preventing weight gain.

Propionate is one of the more mechanistically interesting short-chain fatty acids, but the human evidence is narrower than a generic weight-loss framing suggests. Inulin-propionate ester can reduce acute energy intake and produce useful mechanistic signals, yet the strongest 12-month trial did not confirm a meaningful long-term advantage over inulin control.

Targeted colonic propionate delivery can modulate appetite and metabolic signaling pathways, but long-term clinical superiority over active fiber controls is not firmly established.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Short-term appetite/energy-intake reduction (mixed-moderate certainty)
  • Mixed effects on long-term weight-gain prevention

Secondary Outcomes

  • Potential insulin-sensitivity improvements versus low-fermentable control
  • Mechanistic changes in food-reward and inflammatory/metabolomic signatures

Safety

Contraindications and Interactions

Contraindications

  • Severe fermentable-fiber intolerance
  • Active severe GI disease without guidance
  • Pregnancy/lactation without evidence-guided supervision

Side effects

  • Bloating
  • Gas
  • Mild GI discomfort

Interactions

  • Additive GI effects with high-fermentable prebiotics
  • Potential overlap with other appetite/metabolic supplements
  • No major direct drug interaction pattern established

Avoid if

  • Persistent GI intolerance despite titration
  • Severe uncontrolled metabolic disease without clinician supervision
  • Expectation of standalone weight-loss efficacy

Evidence

Study-level References

propionate-SRC-001Acute crossover plus 24-week randomized controlled study.
Sourceopen_in_new

Chambers ES, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744-1754. doi:10.1136/gutjnl-2014-307913. PMID:25500202.

Population: Overweight adults.

Dose protocol: IPE 10 g/day versus inulin control.

Key findings: Reduced energy intake and favorable weight/adiposity trajectory.

Notes: Innovative design but modest sample and product-specific.

Paper content

Reduced energy intake and favorable weight/adiposity trajectory.

propionate-SRC-002Randomized controlled crossover trial.
Sourceopen_in_new

Polyviou T, et al. Randomised clinical study: inulin short-chain fatty acid esters for targeted delivery of short-chain fatty acids to the human colon. Aliment Pharmacol Ther. 2016;44(7):662-672. doi:10.1111/apt.13749. PMID:27464984.

Population: Adult human participants.

Dose protocol: IPE variants (10 g/day) versus inulin control.

Key findings: IPE-27 reduced ad libitum intake versus control.

Notes: Mechanistic trial with short duration.

Paper content

IPE-27 reduced ad libitum intake versus control.

propionate-SRC-003Randomized, double-blind, placebo-controlled crossover trial.
Sourceopen_in_new

Chambers ES, et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity... Gut. 2019;68(8):1430-1438. doi:10.1136/gutjnl-2019-318424. PMID:30971437.

Population: 12 non-diabetic adults with overweight/obesity.

Dose protocol: 20 g/day IPE, inulin, and cellulose over 42-day periods.

Key findings: IPE and inulin improved HOMA versus cellulose, with distinct biomarker patterns.

Notes: Small sample, mechanistic depth high.

Paper content

IPE and inulin improved HOMA versus cellulose, with distinct biomarker patterns.

propionate-SRC-004Randomized parallel trial.
Sourceopen_in_new

Chambers ES, et al. The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):372-376. doi:10.1111/dom.13500. PMID:30098126.

Population: 18 adults with NAFLD.

Dose protocol: 20 g/day IPE vs inulin for 42 days.

Key findings: No significant between-group primary difference, possible attenuation of inulin-associated IHCL increase.

Notes: Small sample and short duration.

Paper content

No significant between-group primary difference; possible attenuation of inulin-associated IHCL increase.

propionate-SRC-005Multicentre, double-blind, randomized, parallel-group trial
Sourceopen_in_new

Pugh JE, et al. Increase in colonic propionate as a method of preventing weight gain over 12 months in adults aged 20-40 years (iPREVENT). A multi-centre, double-blind, randomised, parallel-group trial. EClinicalMedicine. 2024;76:102844. doi:10.1016/j.eclinm.2024.102844. PMID:39391015.

Population: Adults aged 20 to 40 years at risk of weight gain and living with overweight.

Dose protocol: 10 g/day IPE vs inulin for 12 months.

Key findings: No significant between-group adjusted weight-gain difference.

Notes: Strong longer-term design, compliance moderate.

Paper content

This 12-month randomized trial tested whether inulin-propionate ester could prevent weight gain better than inulin alone in younger adults with overweight. It did not confirm a significant between-group advantage on adjusted body-weight change. That result is important because it counterbalances earlier short-term or mechanistic propionate studies and argues against overstating propionate as a reliable weight-gain-prevention tool.

propionate-SRC-006Randomized crossover mechanistic fMRI study.
Sourceopen_in_new

Byrne CS, et al. Increased colonic propionate reduces anticipatory reward responses in the human striatum to high-energy foods. Am J Clin Nutr. 2016;104(1):5-14. doi:10.3945/ajcn.115.126706. PMID:27169834.

Population: 20 healthy non-obese men (18 analyzable fMRI datasets).

Dose protocol: IPE vs inulin acute testing.

Key findings: Reduced reward-region response to high-energy food and lower ad libitum intake.

Notes: Small sample, mechanistic endpoint.

Paper content

Reduced reward-region response to high-energy food and lower ad libitum intake.

propionate-SRC-007Randomized crossover study.
Sourceopen_in_new

Byrne CS, et al. Effects of Inulin Propionate Ester Incorporated into Palatable Food Products on Appetite and Resting Energy Expenditure. Nutrients. 2019;11(4):861. doi:10.3390/nu11040861. PMID:30995824.

Population: 21 healthy overweight/obese adults.

Dose protocol: IPE-containing foods (10 g/day equivalent) vs inulin control.

Key findings: Lower ad libitum intake after IPE formulation.

Notes: Short-term and product-formulation specific.

Paper content

Lower ad libitum intake after IPE formulation.

Guides

Setup

Help